JP2002544176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002544176A5 JP2002544176A5 JP2000616824A JP2000616824A JP2002544176A5 JP 2002544176 A5 JP2002544176 A5 JP 2002544176A5 JP 2000616824 A JP2000616824 A JP 2000616824A JP 2000616824 A JP2000616824 A JP 2000616824A JP 2002544176 A5 JP2002544176 A5 JP 2002544176A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- parts
- gum
- hereinafter referred
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 description 22
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 208000028299 esophageal disease Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 229960000333 benzydamine Drugs 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229960002688 choline salicylate Drugs 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 208000023668 Pharyngeal disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000033420 disorder of pharynx Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9910212.1A GB9910212D0 (en) | 1999-05-05 | 1999-05-05 | Improvements in or relating to organic compositions |
| GB9910212.1 | 1999-05-05 | ||
| PCT/GB2000/001711 WO2000067799A1 (en) | 1999-05-05 | 2000-05-04 | Compositions for treatment of disorders of the oesophagus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002544176A JP2002544176A (ja) | 2002-12-24 |
| JP2002544176A5 true JP2002544176A5 (https=) | 2007-06-28 |
Family
ID=10852720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000616824A Abandoned JP2002544176A (ja) | 1999-05-05 | 2000-05-04 | 食道の疾患の治療のための組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6610667B1 (https=) |
| EP (2) | EP1614431B1 (https=) |
| JP (1) | JP2002544176A (https=) |
| CN (1) | CN1173743C (https=) |
| AR (1) | AR023876A1 (https=) |
| AT (2) | ATE417602T1 (https=) |
| AU (1) | AU774966B2 (https=) |
| BR (1) | BR0010209A (https=) |
| CA (1) | CA2371031C (https=) |
| DE (2) | DE60023873T2 (https=) |
| ES (1) | ES2251997T3 (https=) |
| GB (2) | GB9910212D0 (https=) |
| PL (1) | PL199445B1 (https=) |
| WO (1) | WO2000067799A1 (https=) |
| ZA (1) | ZA200109073B (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2368013B (en) * | 2001-02-19 | 2004-07-28 | Richard Orlando Brown | An antacid composition which comprise multiple pharmacologically active ingredients for the symptomatic management of pain |
| GB2398496A (en) * | 2003-02-20 | 2004-08-25 | Reckitt Benckiser Healthcare | Suspensions of water-swellable polymer particles which are substantially water-free or contain insufficient water to fully swell the particles |
| US20040185119A1 (en) * | 2003-02-26 | 2004-09-23 | Theuer Richard C. | Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency |
| ITRM20030154A1 (it) * | 2003-04-03 | 2004-10-04 | D M G Italia S R L | Sciroppo antireflusso. |
| CN1780880B (zh) * | 2003-04-25 | 2010-04-28 | 雷克特本克斯尔保健(英国)有限公司 | 可增稠的组合物 |
| WO2006085987A2 (en) | 2004-07-09 | 2006-08-17 | University Of Iowa Research Foundation | Rna interference in respiratory epitheial cells |
| FR2876581B1 (fr) * | 2004-10-20 | 2007-05-18 | Interpharm Dev | Composition bioadhesive a liberation programmee |
| JP4775807B2 (ja) * | 2004-12-02 | 2011-09-21 | 株式会社 メドレックス | 局所麻酔薬物含有ゼリー剤 |
| US8597709B2 (en) | 2005-04-12 | 2013-12-03 | Inovobiologic Inc. | Dietary supplement and methods of use |
| US8062686B2 (en) | 2005-04-12 | 2011-11-22 | InovoBiologics, Inc. | Dietary supplement, and methods of use |
| EP1931222B1 (en) * | 2005-10-05 | 2012-02-15 | FMC Biopolymer AS | Gelling compositions and methods |
| EP1859786A1 (en) * | 2006-05-16 | 2007-11-28 | Frutarom Netherlands B.V. | A method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (GERD) by specific polysaccharides |
| BRPI0704542B8 (pt) * | 2007-05-15 | 2021-05-25 | Univ Estadual Campinas Unicamp | composição farmacêutica, processo de obtenção da composição farmacêutica, uso de uma quantidade farmaceuticamente eficaz de anestésico e agente gelificante, produto e método de tratamento |
| AU2014262248B2 (en) * | 2007-07-30 | 2017-05-04 | Inovobiologic, Inc. | Dietary fiber composition comprising glucomannan, xanthan gum, alginate and lipid |
| US8143314B1 (en) | 2007-09-13 | 2012-03-27 | Robert Carl Stover | Methods and formulations for treating ineffective or decreased esophageal motility |
| EP2214679B1 (en) * | 2007-11-13 | 2019-03-27 | Meritage Pharma, Inc. | Corticosteroid compositions |
| US20090148530A1 (en) * | 2007-12-08 | 2009-06-11 | Jamie Koufman | Method for prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin |
| US20090145433A1 (en) * | 2007-12-08 | 2009-06-11 | Michael James | Apparatus for dispensing a powdered composition into the aerodigestive tract |
| PL2240018T3 (pl) * | 2008-01-04 | 2017-01-31 | Schabar Res Ass Llc | Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy |
| AR070593A1 (es) * | 2008-02-08 | 2010-04-21 | Colgate Palmolive Co | Composiciones efervescentes |
| PL2296670T3 (pl) | 2008-05-13 | 2013-07-31 | Apharm Srl | Doustne zastosowanie glikozaminoglikanu i kompozycje |
| BRPI0912028A2 (pt) * | 2008-05-15 | 2015-10-06 | Firmenich & Cie | sistema de liberação para um ingrediente ativo. |
| WO2010108494A1 (en) * | 2009-03-25 | 2010-09-30 | S-Biotek Holding Aps | Dayspepsia treatment with alginate |
| EP2435021B1 (en) | 2009-05-25 | 2013-07-03 | Pharcoterm S.R.L. | Use of a glycosaminoglycan fixed combination and chewable composition comprising said fixed combination |
| TR201005241A1 (tr) * | 2010-05-25 | 2012-01-23 | Sanovel �La� San. Ve T�C. A.�. | Kontrollü salım sağlayan pregabalin solüsyon formülasyonu. |
| ITRM20120041A1 (it) | 2012-02-08 | 2013-08-09 | Dicofarm Spa | "prodotto a base di glucomannano e chitosano utile per il trattamento del reflusso gastroesofageo" |
| US9452135B2 (en) | 2012-03-20 | 2016-09-27 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
| US9636360B2 (en) * | 2012-09-18 | 2017-05-02 | pH Science Holdings, Inc | Method and composition for treating gastro-esophageal disorders |
| IT201600088648A1 (it) * | 2016-08-31 | 2018-03-03 | Alpiflor S R L | Composizione nutrizionale o farmaceutica ed integratore alimentare contenente detta compsizione nutrizionale o farmaceutica |
| IT201600121601A1 (it) * | 2016-11-30 | 2018-05-30 | Nekkar Lab Srl | Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo |
| IT201600121617A1 (it) * | 2016-11-30 | 2018-05-30 | Nekkar Lab Srl | Composizione per il trattamento del reflusso gastroesofageo |
| CN106420773A (zh) * | 2016-12-21 | 2017-02-22 | 郑州莉迪亚医药科技有限公司 | 一种治疗放射性肠炎的中西药组合物及其制备方法和应用 |
| IT201700108526A1 (it) | 2017-09-28 | 2019-03-28 | Alfasigma Spa | Composizioni orali per il trattamento del refluso gastroesofageo. |
| IL312094A (en) * | 2018-03-02 | 2024-06-01 | Pharagen Llc | Formulations treating acid reflux comprising sodium alginate |
| WO2019172261A1 (ja) * | 2018-03-05 | 2019-09-12 | 国立大学法人東京大学 | 食道狭窄防止材料 |
| CN109432232B (zh) * | 2018-12-07 | 2021-11-26 | 纽湃腾（北京）医药科技有限公司 | 一种改善调节胃食管反流的海藻酸盐组合物及应用 |
| CN109432233A (zh) * | 2018-12-07 | 2019-03-08 | 纽湃腾（北京）医药科技有限公司 | 一种含有猴头菇提取物的抑反流护胃组合物及应用 |
| CN110840853A (zh) * | 2019-10-26 | 2020-02-28 | 张强 | 胃镜检查用咀嚼或含化型口咽部局麻药及服用方法 |
| US12514846B2 (en) | 2020-07-15 | 2026-01-06 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach |
| CA3124579C (en) | 2020-07-15 | 2026-03-31 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
| EP4181912A1 (en) | 2020-07-15 | 2023-05-24 | Schabar Research Associates LLC | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
| IT202000031421A1 (it) * | 2020-12-18 | 2022-06-18 | Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L | Composizione multicomponente comprendente saccarosio solfato o suoi derivati per il trattamento del reflusso gastrico |
| PL4262824T3 (pl) * | 2020-12-18 | 2026-03-30 | Drugs Minerals And Generics Italia S.R.L. In Forma Abbreviata D.M.G. Italia S.R.L. | Wieloskładnikowa kompozycja zawierająca siarczan sacharozy, alginian i gumę gellanową do leczenia refluksu żołądkowego |
| IT202000031433A1 (it) * | 2020-12-18 | 2022-06-18 | Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L | Composizioni comprendenti saccarosio octasolfato per il trattamento del reflusso gastrico |
| IT202000031409A1 (it) * | 2020-12-18 | 2022-06-18 | Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L | Composizione multicomponente comprendente gomma gellano e suo uso per il trattamento del reflusso gastrico |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57133170A (en) * | 1981-02-12 | 1982-08-17 | Kikusui Kagaku Kogyo Kk | Thermochromic coating compound with colorful pattern |
| US4717713A (en) * | 1983-10-31 | 1988-01-05 | Research Corporation | Controlled release liquid pharmaceutical |
| US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
| GB8911177D0 (en) * | 1989-05-16 | 1989-07-05 | Vilain Jean | Alginate gel pharmaceutical product |
| PL170554B1 (pl) * | 1991-12-17 | 1996-12-31 | Fuisz Technologies Ltd | Sposób wytwarzania kompozycji przeciwwrzodowej PL PL PL |
| GB9322314D0 (en) * | 1993-10-29 | 1993-12-15 | Scherer Ltd R P | Foam generating capsules |
| GB9708773D0 (en) * | 1997-04-30 | 1997-06-25 | Reckitt & Colmann Prod Ltd | Organic compositions |
| US6030641A (en) * | 1997-06-03 | 2000-02-29 | Uni Colloid Kabushiki Kaisha | Sustained release capsule and method for preparing the same |
-
1999
- 1999-05-05 GB GBGB9910212.1A patent/GB9910212D0/en not_active Ceased
-
2000
- 2000-05-04 ES ES00927500T patent/ES2251997T3/es not_active Expired - Lifetime
- 2000-05-04 PL PL351134A patent/PL199445B1/pl unknown
- 2000-05-04 US US09/979,538 patent/US6610667B1/en not_active Expired - Fee Related
- 2000-05-04 CN CNB008069573A patent/CN1173743C/zh not_active Expired - Fee Related
- 2000-05-04 DE DE60023873T patent/DE60023873T2/de not_active Expired - Lifetime
- 2000-05-04 AU AU45900/00A patent/AU774966B2/en not_active Ceased
- 2000-05-04 AT AT05019522T patent/ATE417602T1/de not_active IP Right Cessation
- 2000-05-04 BR BR0010209-1A patent/BR0010209A/pt active Search and Examination
- 2000-05-04 EP EP05019522A patent/EP1614431B1/en not_active Expired - Lifetime
- 2000-05-04 GB GB0010669A patent/GB2349570B/en not_active Expired - Lifetime
- 2000-05-04 EP EP00927500A patent/EP1173218B1/en not_active Expired - Lifetime
- 2000-05-04 JP JP2000616824A patent/JP2002544176A/ja not_active Abandoned
- 2000-05-04 CA CA002371031A patent/CA2371031C/en not_active Expired - Fee Related
- 2000-05-04 WO PCT/GB2000/001711 patent/WO2000067799A1/en not_active Ceased
- 2000-05-04 AT AT00927500T patent/ATE308997T1/de not_active IP Right Cessation
- 2000-05-04 DE DE69940131T patent/DE69940131D1/de not_active Expired - Lifetime
- 2000-05-05 AR ARP000102198A patent/AR023876A1/es unknown
-
2001
- 2001-11-01 ZA ZA200109073A patent/ZA200109073B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002544176A5 (https=) | ||
| CA2371031C (en) | Compositions for treatment of disorders of the oesophagus | |
| CN1159000C (zh) | 口腔释放系统 | |
| JP2002523354A (ja) | 口腔用液体粘膜粘着性組成物 | |
| JP2002523353A (ja) | 経口液体粘膜接着性組成物 | |
| JPH09510703A (ja) | 経口ビヒクル組成物 | |
| JP2010539096A (ja) | 咽喉、食道及び胃の治療のための局所的に活性である成分を放出する接着トローチ | |
| JP2006516648A5 (https=) | ||
| DE59702733D1 (de) | Gut schluckbare orale arzneiform | |
| JP2013536874A (ja) | 鼻腔噴霧剤 | |
| KR20120112644A (ko) | 록소프로펜 함유 의약 조성물 | |
| RU2011110715A (ru) | Улучшение композиций или того, что имеет отношение к композициям | |
| JP2008013542A (ja) | 去痰又は気道杯細胞過形成抑制のための医薬組成物 | |
| CN111491616A (zh) | 用于治疗gerd患者亚群的基于透明质酸和硫酸软骨素及其盐的可吸吮和/或口内融化的片剂 | |
| JP2008115167A (ja) | トラネキサム酸を含有する気道杯細胞過形成抑制剤 | |
| JP4457422B2 (ja) | 点鼻組成物 | |
| JP2002523355A (ja) | 口腔用液体粘膜粘着性組成物 | |
| AU2019396829B2 (en) | Adhesive pad | |
| JPH04173730A (ja) | 徐放性口腔内疾患治療剤およびその製法 | |
| EP2328568A1 (en) | Chewable formulation comprising alginate, bicarbonate and carbonate | |
| JP2014070024A (ja) | フェニルプロピオン酸系消炎鎮痛薬を含有する医薬組成物 | |
| JP5670006B2 (ja) | 去痰剤を含有する医薬組成物 | |
| JP4444721B2 (ja) | 医薬組成物 | |
| JPS59196823A (ja) | 皮膚および粘膜の真菌症治療用外用剤 | |
| JP2002522376A5 (https=) |